202931-88-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
1-Methyl-1H-1,2,3-triazole-5-carbaldehyde is utilized as a key intermediate in the synthesis of a diverse range of pharmaceuticals and agrochemicals. Its ability to react with nucleophiles makes it a valuable component in creating new molecules with specific therapeutic or pesticidal properties.
Used in Organic Chemistry:
As a building block, 1-Methyl-1H-1,2,3-triazole-5-carbaldehyde is employed in organic chemistry for the construction of complex organic molecules. Its structural features facilitate the formation of new compounds with potential applications in various fields.
Used in Drug Design and Development:
Due to its unique chemical properties, 1-Methyl-1H-1,2,3-triazole-5-carbaldehyde is applied in drug design and development. It aids in the creation of novel drug candidates that can target specific biological pathways or interact with particular receptors, contributing to the advancement of medicinal chemistry.

Upstream product

• 16681-65-5 1-methyl-1,2,3-triazole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 716361-91-0 1-methyl-1H-1,2,3-triazole-5-carboxylic acid 
• 1599529-57-3 (4-chloro-2-methoxy-3-(4-(trifluoromethyl)benzyl)quinoline-6-yl)(1-methyl-1H-1,2,3-triazol-5-yl)methanol 
• 1219004-78-0 (4S)-3-[(2S,3S)-2-(biphenyl-4-ylmethoxy)-3-hydroxy-2-methyl-3-(1-methyl-1H-1,2,3-triazol-5-yl)propanoyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one 

Relevant academic research and scientific papers

SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of FormulaI.wherein:R1, R2, R3, R4, R5, R6, R7, R8, and R9are defined in the specification.The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain

Voltage-gated sodium channels, in particular Nav1.8, can be targeted for the treatment of neuropathic and inflammatory pain. Herein, we described the optimization of Nav1.8 modulator series to deliver subtype selective, state, and use-dependent chemical matter that is efficacious in preclinical models of neuropathic and inflammatory pain. (Chemical Presented).

SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

PYRIDINE DERIVATIVES

The present invention relates to compounds of the formula (I): (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.

Substituted triazolo-pyridazine derivatives as ligands for GABA receptors

Substituted triazolo-pyridazine derivative compounds represented by wherein the variables are disclosed herein are selective ligands for GABA-A receptors, particularly for the α2 and/or α3 subunits.